JPH06507908A - 関節炎の処理のための放射性ラベルされた金属結合性タンパク質 - Google Patents
関節炎の処理のための放射性ラベルされた金属結合性タンパク質Info
- Publication number
- JPH06507908A JPH06507908A JP5500432A JP50043293A JPH06507908A JP H06507908 A JPH06507908 A JP H06507908A JP 5500432 A JP5500432 A JP 5500432A JP 50043293 A JP50043293 A JP 50043293A JP H06507908 A JPH06507908 A JP H06507908A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- rheumatoid arthritis
- chelating agent
- molecular weight
- metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052751 metal Inorganic materials 0.000 title claims description 60
- 239000002184 metal Substances 0.000 title claims description 60
- 102000014914 Carrier Proteins Human genes 0.000 title claims description 25
- 108091008324 binding proteins Proteins 0.000 title claims description 25
- 206010003246 arthritis Diseases 0.000 title claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 239000002738 chelating agent Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 17
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- 102000008857 Ferritin Human genes 0.000 claims description 12
- 108050000784 Ferritin Proteins 0.000 claims description 12
- 238000008416 Ferritin Methods 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- -1 Re-186 Chemical compound 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 102000004338 Transferrin Human genes 0.000 claims description 4
- 108090000901 Transferrin Proteins 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000012581 transferrin Substances 0.000 claims description 4
- 102000001554 Hemoglobins Human genes 0.000 claims description 2
- 108010054147 Hemoglobins Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 108060003552 hemocyanin Proteins 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 8
- 241000283073 Equus caballus Species 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 description 21
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- 210000001179 synovial fluid Anatomy 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 150000002739 metals Chemical class 0.000 description 10
- 230000001588 bifunctional effect Effects 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 239000013522 chelant Substances 0.000 description 4
- YSYKRGRSMLTJNL-URARBOGNSA-N dTDP-alpha-D-glucose Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)C1 YSYKRGRSMLTJNL-URARBOGNSA-N 0.000 description 4
- 229940120146 EDTMP Drugs 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- NFDRPXJGHKJRLJ-UHFFFAOYSA-N edtmp Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CCN(CP(O)(O)=O)CP(O)(O)=O NFDRPXJGHKJRLJ-UHFFFAOYSA-N 0.000 description 3
- 108091005979 iodinated proteins Proteins 0.000 description 3
- 238000004255 ion exchange chromatography Methods 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RFJZAVZNNXEQTM-UHFFFAOYSA-N 2-amino-2-[4,7,10-tris(carboxymethyl)-2-phenyl-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)C(N)N1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1C1=CC=CC=C1 RFJZAVZNNXEQTM-UHFFFAOYSA-N 0.000 description 1
- JUIKUQOUMZUFQT-UHFFFAOYSA-N 2-bromoacetamide Chemical compound NC(=O)CBr JUIKUQOUMZUFQT-UHFFFAOYSA-N 0.000 description 1
- PFEFOHMLVFUELJ-UHFFFAOYSA-N 3-sulfanylideneisoindol-1-one Chemical compound C1=CC=C2C(=O)NC(=S)C2=C1 PFEFOHMLVFUELJ-UHFFFAOYSA-N 0.000 description 1
- 241000212977 Andira Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229910052692 Dysprosium Inorganic materials 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229910052689 Holmium Inorganic materials 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical class OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000287462 Phalacrocorax carbo Species 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000012954 diazonium Substances 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-O diazynium Chemical compound [NH+]#N IJGRMHOSHXDMSA-UHFFFAOYSA-O 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical class [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000031787 nutrient reservoir activity Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- CTRLRINCMYICJO-UHFFFAOYSA-N phenyl azide Chemical compound [N-]=[N+]=NC1=CC=CC=C1 CTRLRINCMYICJO-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical class NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052706 scandium Inorganic materials 0.000 description 1
- SIXSYDAISGFNSX-UHFFFAOYSA-N scandium atom Chemical compound [Sc] SIXSYDAISGFNSX-UHFFFAOYSA-N 0.000 description 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/008—Peptides; Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (18)
- 1.金属結合性タンパク質に結合される治療用放射性核種を含んで成る化合物で あって、ここで前記放射性核種が2時間〜7日間の半減期を有するβ−エミッタ ーであり、そして前記タンパク質が50,000以上の分子量を有することを特 徴とする化合物。
- 2.前記タンパク質がフェリチン、トランスフェリン、ヘモグロビン、セルロプ ラスミン又はヘモシアニンである請求の範囲第1項記載の化合物。
- 3.前記放射性核種がHo−166,Sm−153,Re−186,Y−90, La−140,Gd−159,Yb−175,Rh−105,Lu−177,I n−115m,Dy−165,Re−188又はSc−47である請求の範囲第 1項記載の化合物。
- 4.医薬として使用するための請求の範囲第1〜3のいづれか1項記載の化合物 。
- 5.リウマチ様関節炎を処理するための剤として使用するための請求の範囲第4 項記載の化合物。
- 6.1又は複数の医薬的に許容できるキャリヤーと共に活性成分として請求の範 囲第1〜3のいづれか1項記載の化合物を含んで成る医薬製剤。
- 7.医薬として使用するための請求の範囲第6項記載の製剤。
- 8.リウマチ様関節炎剤として使用するための請求の範囲第7項記載の製剤。
- 9.請求の範囲第1〜3のいづれか1項記載の化合物の有効量を動物に投与する ことを含んで成る、リウマチ様関節炎の処理の必要な動物におけるそのようなリ ウマチ様関節炎を処理するための方法。
- 10.前記有効量が5Greys〜1,500Greysである請求の範囲第9 項記載の方法。
- 11.請求の範囲第6項記載の製剤の有効量を動物に投与することを含んで成る 、リウマチ様関節炎の処理の必要な動物におけるそのようなリウマチ様関節炎を 処理するための方法。
- 12.およそ50,000以上の分子量を有するタンパク質、該タンパク質に共 有結合される二官能価キレート化剤及び該二官能価キレート化剤にキレート化さ れる、2時間〜7日間の半減期を有するβ−エミッターである治療用放射性核種 を含んで成る、リウマチ様関節炎の処理において剤として使用するための化合物 。
- 13.リウマチ様関節炎の処理において剤として使用するための活性成分として 、およそ50,000以上の分子量を有するタンパク質、該タンパク質に共有結 合される二官能価キレート化剤及び該二官能価キレート化剤にキレート化される 、2時間〜7日間の半減期を有するβ−エミッターである治療用放射性核種を含 んで成る製剤であって、ここで前記活性成分が1又は複数の医薬的に許容できる キャリヤーに間達している製剤。
- 14.50,000以上の分子量を有するタンパク質、該タンパク質に共有結合 される二官能価キレート化剤及び該二官能価キレート化剤にキレート化される、 2時間〜7日間の半減期を有するβ−エミッターである治療用核種を含んで成る 化合物の有効量を動物に投与することを含んで成る、リウマチ様関節炎の処理の 必要な動物におけるそのようなリウマチ様関節炎を処理するための方法。
- 15.50,000以上の分子量を有するタンパク質、該タンパク質に共有結合 される二官能価キレート化剤及び該二官能価キレート化剤にキレート化される、 2時間〜7日間の半減期を有するβ−エミッターである治療用核種を含んで成る 製剤の有効量を動物に投与することを含んで成る、リウマチ様関節炎の処理の必 要な動物におけるそのようなリウマチ様関節炎を処理するための方法。
- 16.前記有効量が5Greys〜1,500Greysの用量である請求の範 囲第14又は15項記載の方法。
- 17.前記二官能価キレート化剤がポリアミノカルボキシレート又はポリアミノ ホスホネートキレート化成分を含む請求の範囲第12〜16項記載のいづれかの もの。
- 18.リウマチ様関節炎を処理するためのキットであって、第1区画室に2時間 〜7日間の半減期を有するβ−エミッターである放射性核種及び第2区画室に5 0,000以上の分子量を有する金属結合性タンパク質を含んで成るキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/707,719 US5133956A (en) | 1991-05-30 | 1991-05-30 | Radiolabeled metal-binding protein for the treatment of arthritis |
US707,719 | 1991-05-30 | ||
PCT/US1992/004139 WO1992021379A1 (en) | 1991-05-30 | 1992-05-15 | Radiolabeled metal-binding protein for the treatment of arthritis |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH06507908A true JPH06507908A (ja) | 1994-09-08 |
JP3535154B2 JP3535154B2 (ja) | 2004-06-07 |
Family
ID=24842876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50043293A Expired - Fee Related JP3535154B2 (ja) | 1991-05-30 | 1992-05-15 | 関節炎の処理のための放射性ラベルされた金属結合性タンパク質 |
Country Status (7)
Country | Link |
---|---|
US (1) | US5133956A (ja) |
EP (1) | EP0586562B1 (ja) |
JP (1) | JP3535154B2 (ja) |
AU (1) | AU2156792A (ja) |
CA (1) | CA2109208C (ja) |
DE (1) | DE69230912T2 (ja) |
WO (1) | WO1992021379A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5320824A (en) * | 1989-10-12 | 1994-06-14 | Mallinckrodt Medical, Inc. | Radionuclide labelled particles useful for radiation synovectomy |
US5137709A (en) * | 1991-02-15 | 1992-08-11 | The Dow Chemical Company | Layered mixed metal hydroxides for the stabilization of radioactive colloids |
US5443813A (en) * | 1991-06-06 | 1995-08-22 | Associated Universities, Inc. | Loading and conjugating cavity biostructures |
US5403573A (en) * | 1992-04-23 | 1995-04-04 | The Curators Of The University Of Missouri | Radiolabeled protein composition and method for radiation synovectomy |
WO1995016463A1 (en) * | 1992-09-23 | 1995-06-22 | The Dow Chemical Company | Radioactive compositions and their use for radiation ablation treatment |
US6770261B2 (en) | 1995-06-02 | 2004-08-03 | Research Corporation Technologies | Magnetic resonance imaging agents for the detection of physiological agents |
US6713045B1 (en) | 1995-06-02 | 2004-03-30 | Research Corporation Technologies, Inc. | Targeted magnetic resonance imaging agents for the detection of physiological processes |
US6302909B1 (en) | 1996-07-31 | 2001-10-16 | St. Jude Medical, Inc. | Calcification-resistant biomaterials |
US5871436A (en) * | 1996-07-19 | 1999-02-16 | Advanced Cardiovascular Systems, Inc. | Radiation therapy method and device |
US5900228A (en) | 1996-07-31 | 1999-05-04 | California Institute Of Technology | Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye |
US5782740A (en) * | 1996-08-29 | 1998-07-21 | Advanced Cardiovascular Systems, Inc. | Radiation dose delivery catheter with reinforcing mandrel |
US6005083A (en) * | 1997-03-28 | 1999-12-21 | Neorx Corporation | Bridged aromatic substituted amine ligands with donor atoms |
US6210312B1 (en) | 1997-05-20 | 2001-04-03 | Advanced Cardiovascular Systems, Inc. | Catheter and guide wire assembly for delivery of a radiation source |
US6713046B1 (en) | 1997-10-27 | 2004-03-30 | Research Corporation Technologies | Magnetic resonance imaging agents for the delivery of therapeutic agents |
CA2309749A1 (en) * | 1997-11-17 | 1999-05-27 | Research Corporation Technologies, Inc. | Magnetic resonance imaging agents for the detection of physiological agents |
US6254635B1 (en) | 1998-02-02 | 2001-07-03 | St. Jude Medical, Inc. | Calcification-resistant medical articles |
US6159139A (en) * | 1998-02-17 | 2000-12-12 | Advanced Cardiovascular Systems Inc. | Radiation delivery catheter with a spring wire centering mechanism |
US6224535B1 (en) | 1998-02-17 | 2001-05-01 | Advanced Cardiovascular Systems, Inc. | Radiation centering catheters |
US6159140A (en) * | 1998-02-17 | 2000-12-12 | Advanced Cardiovascular Systems | Radiation shielded catheter for delivering a radioactive source and method of use |
US6605031B1 (en) | 1999-09-22 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stepped centering balloon for optimal radiation delivery |
US6582417B1 (en) * | 1999-09-22 | 2003-06-24 | Advanced Cardiovascular Systems, Inc. | Methods and apparatuses for radiation treatment |
US7994449B2 (en) | 2000-02-16 | 2011-08-09 | Advanced Cardiovascular Systems, Inc. | Square-wave laser bonding |
US7163504B1 (en) | 2000-02-16 | 2007-01-16 | Advanced Cardiovascular Systems, Inc. | Multi-lumen fluted balloon radiation centering catheter |
US6673333B1 (en) | 2000-05-04 | 2004-01-06 | Research Corporation Technologies, Inc. | Functional MRI agents for cancer imaging |
WO2002006287A2 (en) | 2000-07-17 | 2002-01-24 | California Institute Of Technology | Macrocyclic mri contrast agents |
WO2002028441A2 (en) | 2000-10-04 | 2002-04-11 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
US20030004236A1 (en) * | 2001-04-20 | 2003-01-02 | Meade Thomas J. | Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances |
WO2002087632A1 (en) * | 2001-05-02 | 2002-11-07 | Metaprobe, Inc. | High throughput screening methods using magnetic resonance imaging agents |
US20030135108A1 (en) * | 2001-05-02 | 2003-07-17 | Silva Robin M. | High throughput screening methods using magnetic resonance imaging agents |
DE10135356C1 (de) * | 2001-07-20 | 2003-04-17 | Schering Ag | Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen |
US20030198597A1 (en) * | 2002-04-22 | 2003-10-23 | Meade Thomas J. | Novel macrocyclic activatible magnetic resonance imaging contrast agents |
EP1932850A1 (en) * | 2006-12-11 | 2008-06-18 | Thermphos Trading GmbH | Phosphonate compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3663685A (en) * | 1968-04-01 | 1972-05-16 | Minnesota Mining & Mfg | Biodegradable radioactive particles |
DE2543349C2 (de) * | 1975-09-29 | 1984-05-10 | Henkel KGaA, 4000 Düsseldorf | Preaparate zur herstellung von99m technetium-radiagnostica |
US4622420A (en) * | 1980-03-18 | 1986-11-11 | The Regents Of The University Of California | Chelating agents and method |
US4448762A (en) * | 1980-11-03 | 1984-05-15 | The United States Of America As Represented By The United States Department Of Energy | Complex of transferrin with ruthenium for medical applications |
AT379304B (de) * | 1981-07-13 | 1985-12-27 | Blum Gmbh Julius | Ausziehvorrichtung fuer schubladen od. dgl. |
US4957939A (en) * | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
US4454106A (en) * | 1982-06-07 | 1984-06-12 | Gansow Otto A | Use of metal chelate conjugated monoclonal antibodies |
US4898724A (en) * | 1984-06-04 | 1990-02-06 | The Dow Chemical Company | Organis amine phosphonic acid complexes for the treatment of calcific tumors |
US4897254A (en) * | 1984-09-21 | 1990-01-30 | The Dow Chemical Company | Radioactive compositions for the treatment of calcific tumors |
US5037630A (en) * | 1985-01-14 | 1991-08-06 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US4849209A (en) * | 1985-06-07 | 1989-07-18 | Cadema Medical Products, Inc. | Treatment of arthritis, including rheumatoid arthritis with 166 Holmium radionuclide |
US4752464A (en) * | 1985-06-07 | 1988-06-21 | Cadema Medical Products, Inc. | Treatment of arthritis, including rheumatoid arthritis, with radioactive isotopes |
US4758429A (en) * | 1985-11-04 | 1988-07-19 | Gordon Robert T | Method for the treatment of arthritis and inflammatory joint diseases |
KR960001742B1 (en) * | 1986-12-30 | 1996-02-05 | Nihon Medi Physics K K | High molecular compound comprising unit of asialoglycoprotein |
US4906450A (en) * | 1987-03-26 | 1990-03-06 | Ephraim Lieberman | Treatment of arthritis, including rheumatoid arthritis, with the radionuclide, tin SN-121 |
US4853209A (en) * | 1987-05-18 | 1989-08-01 | The Dow Chemical Company | Bone marrow suppressing agents |
US4915932A (en) * | 1987-10-14 | 1990-04-10 | Australian Nuclear Science & Technology Organisation | Macroaggregates for radiation synovectomy |
US5039326A (en) * | 1988-01-29 | 1991-08-13 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
US4889707A (en) * | 1988-01-29 | 1989-12-26 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
US5011797A (en) * | 1988-01-29 | 1991-04-30 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
US4882142A (en) * | 1988-12-19 | 1989-11-21 | The Dow Chemical Company | Bone marrow suppressing agents |
US4976950A (en) * | 1988-12-19 | 1990-12-11 | The Dow Chemical Company | Bone marrow suppressing agents |
US4970062A (en) * | 1989-05-30 | 1990-11-13 | The United States Of America As Represented By The United States Department Of Energy | Colloid labelled with radionuclide and method |
-
1991
- 1991-05-30 US US07/707,719 patent/US5133956A/en not_active Expired - Lifetime
-
1992
- 1992-05-15 JP JP50043293A patent/JP3535154B2/ja not_active Expired - Fee Related
- 1992-05-15 DE DE69230912T patent/DE69230912T2/de not_active Expired - Fee Related
- 1992-05-15 EP EP92913058A patent/EP0586562B1/en not_active Expired - Lifetime
- 1992-05-15 WO PCT/US1992/004139 patent/WO1992021379A1/en active IP Right Grant
- 1992-05-15 AU AU21567/92A patent/AU2156792A/en not_active Abandoned
- 1992-05-15 CA CA002109208A patent/CA2109208C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU2156792A (en) | 1993-01-08 |
JP3535154B2 (ja) | 2004-06-07 |
EP0586562A1 (en) | 1994-03-16 |
EP0586562A4 (en) | 1998-01-14 |
EP0586562B1 (en) | 2000-04-12 |
US5133956A (en) | 1992-07-28 |
DE69230912T2 (de) | 2000-12-07 |
CA2109208C (en) | 2003-05-06 |
WO1992021379A1 (en) | 1992-12-10 |
DE69230912D1 (de) | 2000-05-18 |
CA2109208A1 (en) | 1992-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06507908A (ja) | 関節炎の処理のための放射性ラベルされた金属結合性タンパク質 | |
JP3853354B2 (ja) | 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤 | |
CN111491668B (zh) | 一种含有与铅或钍放射性核素连接的psma靶向化合物的络合物 | |
US5876695A (en) | Metal complex-containing pharmaceutical agents | |
CA2371728C (en) | High dose radionuclide complexes for bone marrow suppression | |
US5300281A (en) | Radiolabeled compositions containing a calcific matrix and their use for treatment of arthritis | |
FI92075C (fi) | Menetelmä teknetium-99m:llä leimatun elinspesifisen aineen valmistamiseksi | |
JPH0582368B2 (ja) | ||
US7691985B2 (en) | Skeletal-targeted radiation to treat bone-associated pathologies | |
JPH10501531A (ja) | モノアミン、ジアミド、チオール含有金属キレート剤 | |
JP6734350B2 (ja) | 有利な特性を有する放射性医薬溶液 | |
JP2005516933A (ja) | 放射性医薬による骨髄炎の治療 | |
Weiner et al. | Radionuclides: applications in diagnostic and therapeutic nuclear medicine | |
US5217704A (en) | Methods and materials for the preparation of metal labelled antibody solutions | |
JP2792871B2 (ja) | 金属イオンの除去方法およびそれに用いる溶液 | |
US4042677A (en) | Technetium-99m labeled radiodiagnostic agents and method of preparation | |
US9242016B2 (en) | Gold coated lanthanide nanoparticles | |
JP2003504395A (ja) | 腎臓に有害な可能性のある分子の腎臓取り込みの阻害 | |
TWI278321B (en) | Stabiliser for radiopharmaceuticals | |
Yoneda et al. | Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody | |
JPH0582370B2 (ja) | ||
CA2066779A1 (en) | Stable therapeutic radionuclide compositions and methods for preparation thereof | |
Lashford et al. | Systemic administration of radionuclides in neuroblastoma as planned radiotherapeutic intervention | |
Molinski et al. | Technetium-99m labeled radiodiagnostic agents and method of preparation | |
Zolle et al. | 12.7. 2 99mTc-Diphosphonates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040210 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040311 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080319 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080319 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |